Literature DB >> 7763486

Production of recombinant salmon calcitonin by in vitro amidation of an Escherichia coli produced precursor peptide.

M V Ray1, P Van Duyne, A H Bertelsen, D E Jackson-Matthews, A M Sturmer, D J Merkler, A P Consalvo, S D Young, J P Gilligan, P P Shields.   

Abstract

Salmon calcitonin (sCT) is a 32 amino acid peptide hormone that requires C-terminal amidation for full biological activity. We have produced salmon calcitonin by in vitro amidation of an E. coli produced precursor peptide. Glycine-extended sCT, the substrate for amidation, was produced in recombinant E. coli as part of a fusion with glutathione-S-transferase. The microbially produced soluble fusion protein was purified to near homogeneity by affinity chromatography. Following S-sulfonation of the fusion protein, the glycine-extended peptide was cleaved from the fusion by cyanogen bromide. The S-sulfonated peptide was recovered and enzymatically converted to the amidated peptide in a reaction with recombinant peptidylglycine alpha-amidating enzyme (alpha-AE) secreted from Chinese hamster ovary (CHO) cells. After reformation of the intramolecular disulfide bond, the sCT was purified with a step yield of 60%. The ease and speed of this recombinant process, as well as its potential for scale-up, make it adaptable to production demands for calcitonin, a proven useful agent for the treatment of post-menopausal osteoporosis. Moreover, the relaxed specificity of the recombinant alpha-AE for the penultimate amino acid which is amidated allows the basic process to be applied to the production of other amidated peptides.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7763486     DOI: 10.1038/nbt0193-64

Source DB:  PubMed          Journal:  Biotechnology (N Y)        ISSN: 0733-222X


  8 in total

1.  Genetic construction and properties of a diphtheria toxin-related substance P fusion protein: in vitro destruction of cells bearing substance P receptors.

Authors:  C E Fisher; J A Sutherland; J E Krause; J R Murphy; S E Leeman; J C vanderSpek
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

2.  Evidence for substrate preorganization in the peptidylglycine α-amidating monooxygenase reaction describing the contribution of ground state structure to hydrogen tunneling.

Authors:  Neil R McIntyre; Edward W Lowe; Jonathan L Belof; Milena Ivkovic; Jacob Shafer; Brian Space; David J Merkler
Journal:  J Am Chem Soc       Date:  2010-11-02       Impact factor: 15.419

3.  Production of the catalytic core of human peptidylglycine α-hydroxylating monooxygenase (hPHMcc) in Escherichia coli.

Authors:  Sumit Handa; Tyler J Spradling; Daniel R Dempsey; David J Merkler
Journal:  Protein Expr Purif       Date:  2012-04-25       Impact factor: 1.650

Review 4.  Industrial production of recombinant therapeutics in Escherichia coli and its recent advancements.

Authors:  Chung-Jr Huang; Henry Lin; Xiaoming Yang
Journal:  J Ind Microbiol Biotechnol       Date:  2012-01-18       Impact factor: 3.346

Review 5.  Peptidylglycine α-amidating monooxygenase as a therapeutic target or biomarker for human diseases.

Authors:  David J Merkler; Aidan J Hawley; Betty A Eipper; Richard E Mains
Journal:  Br J Pharmacol       Date:  2022-02-28       Impact factor: 9.473

6.  Aspects of antibody-catalyzed primary amide hydrolysis.

Authors:  R C Titmas; T S Angeles; R Sugasawara; N Aman; M J Darsley; G Blackburn; M T Martin
Journal:  Appl Biochem Biotechnol       Date:  1994 May-Jun       Impact factor: 2.926

7.  Biological Insights into Therapeutic Protein Modifications throughout Trafficking and Their Biopharmaceutical Applications.

Authors:  Xiaotian Zhong; Jill F Wright
Journal:  Int J Cell Biol       Date:  2013-04-18

Review 8.  Strategies for Heterologous Expression, Synthesis, and Purification of Animal Venom Toxins.

Authors:  Esperanza Rivera-de-Torre; Charlotte Rimbault; Timothy P Jenkins; Christoffer V Sørensen; Anna Damsbo; Natalie J Saez; Yoan Duhoo; Celeste Menuet Hackney; Lars Ellgaard; Andreas H Laustsen
Journal:  Front Bioeng Biotechnol       Date:  2022-01-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.